Menu Back to DIA-Middle-East-Regulatory-Conference-MERC

Overview

DIA provides the unique platform in the Middle East of connecting experts in the region for collaborative discussion.

Every country throughout the Middle East region is formulating improved regulations for pharmaceutical and biopharmaceutical development. What can we all learn from each other?

The 13th DIA Middle East Regulatory Conference (MERC), shaped in partnership with the EFPIA Middle East Regulatory Network (MERN), is built on the premise that collaboration leads to a more efficient regulatory system that sustains patient access to medicines. This conference, growing in scale every year, brings together health authorities and global stakeholders from across the region and Europe. The conference will discuss country-level progress and challenges, as well as opportunities for increased regional collaboration.

Are you ready to collaborate?

Top 3 Reasons to Attend the 2019 MERC:

  1. Collaborate with Health Authorities from many different countries – Don’t miss this chance to get exposure to the future of health policy in the region
  2. Connect with 300+ participants, representing 27 countries from health authorities and pharmaceutical industry, throughout the Middle East, Europe and globally
  3. Establish leading strategies and processes for getting innovative medicines to patients faster

Who will you meet?

  • Regulatory agencies and ministries of health in the region, experts from international organisations
  • Thought leaders, global and local stakeholders from both local and multinational pharmaceutical companies who are working in the fields of
    • Regulatory affairs, Policy, Government Affairs, Access
    • Pharmacovigilance

To get a feel for the conference view the final programme from the 2017 MERC

Featured topics

  • Regional Developments
  • Good Regulatory Practice & Reliance models
  • Lifecycle Management 
  • HTA Access & Value
  • Innovation in the Pharmaceutical Sector
  • Pharmacovigilance
  • eCTD
  • Regulatory Systems
  • Biosimilars
  • Patient Engagement

Who should attend?

The conference is directed at key stakeholders that are active or are interested in this diverse and changing region, including representatives from regulatory agencies, ministries of health, local and multi-national pharmaceutical companies. You will have the opportunity to meet and exchange views, discuss topics of interest and identify actions to increase patient access to new and improved medicines and therapies:

  • Regulatory Affairs Heads / Officers / Directors / Managers / Specialists
  • Scientific Office Managers
  • Registration Managers
  • Pharmacists
  • Patient Safety Managers / Officers
  • Drug Safety & Quality Assurance Directors / Managers
  • Heads of Market Access
  • Patient Advocates

Program Committee

  • Inas  Chehimi
    Inas Chehimi Head RA Middle East & North Africa
    Novartis Pharma Services AG, United Arab Emirates
  • Catherine  Al Ashram
    Catherine Al Ashram Director Regulatory Affairs ME
    Merck Sharp & Dohme, Jordan
  • Fadila  Lakkis
    Fadila Lakkis Project Manager Officer for Gulf & Near East
    GSK, Lebanon
  • Greg  Jordinson, MSc
    Greg Jordinson, MSc Associate Director, Global Regulatory Affairs
    Janssen R&D, United Kingdom
  • Nadine  Otin
    Nadine Otin President
    PHARMAREG International Consulting, France
  • Paul  Dearden
    Paul Dearden Senior Director, Global Regulatory Policy
    Biogen, United Kingdom
  • Rachelle  Ross
    Rachelle Ross Associate Director, International Regulatory Sciences
    Biogen Idec Ltd, United Kingdom
  • Susanne  Ausborn, PhD
    Susanne Ausborn, PhD Global Head International Regulatory Policy
    F. Hoffmann-La Roche Ltd., Switzerland
  • Sylvie  Meillerais, MSc
    Sylvie Meillerais, MSc Director Global CMC Policy
    MSD (Europe) Inc., Belgium
  • Abdulrahim  Alyahya
    Abdulrahim Alyahya Regulatory Director
    Abbvie, Saudi Arabia
  • Adele  Choueiry
    Adele Choueiry Head, Regulatory Affairs, Levant Region; Lebanon Regulatory Working Group Chair
    Novartis , Lebanon
  • Dina  Fathy
    Dina Fathy Regulatory Affairs Director Gulf
    MSD, United Arab Emirates
  • Mounay Hussein Khafaja, PharmD, MSc
    Mounay Hussein Khafaja, PharmD, MSc Regulatory Affairs Director & Regulatory Center of Excellence, IRWG Group Chair
    Merck, Lebanon
  • Samia Gamal Seleem, PharmD, RAC
    Samia Gamal Seleem, PharmD, RAC Scientific & Regulatory Affairs Director
    Abbvie, Egypt
  • Suha  Abdallah
    Suha Abdallah Associate Director, Regulatory Affairs Levant & Iraq
    Merck Sharp & Dohme Jordan, Jordan
  • Ph. Ahmed  Al Harbi
    Ph. Ahmed Al Harbi Director of Drug Control
    Ministry of Health , Oman
  • Hassaan S  Alwohaibi
    Hassaan S Alwohaibi Executive Director of Regulatory Affairs Directorate
    Saudi Food and Drug Authority (SFDA), Saudi Arabia
  • Mohamed  Hany
    Mohamed Hany Head of Medical Devices Registration
    Ministry of Health and Prevention, UAE, United Arab Emirates
  • Rasha  Ziada
    Rasha Ziada Chairperson of the Central Adminstration of Pharmaceutical Affairs (CAPA)
    Egyptian Ministry of Health and Population, Egypt
  • Sarah  Al Maqseed
    Sarah Al Maqseed Registration and Release Superintendent
    Ministry of Health, Kuwait, Kuwait
  • Shereen  Abdel-Gaward
    Shereen Abdel-Gaward Head of Technical Office, Central Administration of Pharmaceutical Affairs
    Egyptian Ministry of Health and Population, Egypt
  • Wesal  Al Haqish
    Wesal Al Haqish Drug Directorate Director
    Jordan Food and Drug Administration (JFDA), Jordan
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download